Dermatology has evolved from a reliance on off-label medications to the development of a competitive pipeline of disease-modifying biologics and other technologies. Current dermatology dynamics the REACH team is tracking include:
- Expansion of development within less common dermatological conditions beyond Psoriasis and Atopic Dermatitis
- Segmentation of larger dermatological markets into smaller niche markets defined by underlying disease pathophysiology (e.g., Generalized Pustular Psoriasis, Palmoplantar Pustulosis)
- FDA approval of Krystal Biotech’s Vyjuvek, the first topical and redosable gene therapy, for treating Dystrophic Epidermolysis Bullos
Search Dermatology diseases we cover